While humans may have some capacity to reduce plasma methemoglobin (Vandegriff et al., 2006; McGown et al., 1990), this capacity is limited and may be overwhelmed in patients with pre-existing endothelial dysfunction at higher HBOC doses (Biro, 2012; D’Agnillo, 2013). This evidence concerns the gene HBG2 and endothelial dysfunction.